Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford University, through its innovation arm Oxford University Innovation (OUI), is launching support for the creation of impact-driven businesses: social enterprises.

Social enterprises are companies which combine the impact-centric agenda of a charity with the profit generation strategies of a business. How this is achieved differs from company to company, but fundamental to all social enterprise is the concept of replacing the profitability goal at the core of mainstream businesses with an impact mission focused on enacting positive societal or environmental change.

To date, the innovation side of the University has supported creation of two types of business: regular startup businesses created by the student body, and ventures based on intellectual property from the University supported by OUI, known as spinouts. Typically, spinouts are formed around a patentable technology, such as a potential therapeutic candidate or an engineering project. This model has been successful for turning Oxford research into reality, with the University creating over 160 spinout companies since OUI opened its doors in 1987, 19 of which were launched in the past year.

Find out more (University of Oxford website)

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.